From: Reporting of heterogeneity of treatment effect in cohort studies: a review of the literature
Study characteristics | All studies (n = 57) | Studies addressing HTE (n = 31) | Studies not addressing HTE (n = 26) | p-value* |
---|---|---|---|---|
Sample size, Med(Q1-Q3) | 2438(415–19,486) | 7484(1259–70,336) | 470(166–2453) | <0.001 |
Length of follow up (years), Med(Q1-Q3) | 3(1–7) | 5(2.2–11.8) | 1(0.1–4) | 0.002 |
Date of publication | 0.2 | |||
2000–2013 | 28(49) | 18(58) | 10(38.5) | |
2014–2016 | 29(51) | 13(42) | 16(61.5) | |
Journal type, n(%) | <0.001 | |||
High impact factor journals (HIJ) | 28(49) | 22(71) | 6(23) | |
Low impact factor journals (LIJ) | 29(51) | 9(29) | 20(77) | |
Source of funding, n(%) | 0.68 | |||
Industry | 36(63) | 23(74) | 13(19) | |
Other | 10(17) | 5(16) | 5(50) | |
NA | 11(20) | 3(10) | 8(31) | |
Study area, n(%) | 0.02 | |||
Medical | 34(60) | 23(74) | 11(42) | |
Non medical | 23(40) | 8(26) | 15(58) | |
Type of primary outcome, n(%) | 0.05 | |||
Time to event | 26(46) | 18(58) | 8(31) | |
Binary | 16(28) | 5(16) | 11(42) | |
Continuous | 15(26) | 8(26) | 7(27) | |
Main effect of primary outcome, n(%) | 1 | |||
Statistically significant | 36(63) | 20(65) | 16(62) | |
Not statistically significant | 21(37) | 11(35) | 10(38) | |
Analysis of predictive factors on side effects, n(%) | 0(0) | 0(0) | – | |
Prespecification of HTE analysis, n(%) | 30(53) | 30(97) | – | |
Type of HTE analysis, n(%) | ||||
Subgroup | 1(2) | 1(3) | – | |
Adjusted | 23(40) | 23(74) | – | |
Propension | 7(12) | 7(23) | – | |
Predictive variables studied, n(%) | ||||
Age | 13(23) | 18(58) | – | |
Sexe | 7(12) | 7(23) | – | |
Social level | 2(3) | 2(6) | – | |
Genetics | 3(5) | 3(10) | – | |
Treatment | 27(47) | 27(87) | – | |
Comorbidities | 8(14) | 8(26) | – | |
Severity of disease | 6(11) | 6(19) | – | |
Prognostic variables studied, n(%) | 20(35) | 10(32) | 10() | 0.78 |
Analysis of prognostic factors on side effect, n(%) | 0(0) | 0(0) | 0(0) | – |
Interaction test, n(%) | 6(10) | 6(19) | 0(0) | – |